Agile Sciences Awarded NSF Grant to Validate Biofilm Dispersion Technology on Medical Devices

Share Article

Agile Sciences’ proprietary compounds to be tested on implantable medical devices.

Agile Sciences, Inc. has been awarded a $150,000 Phase I SBIR Grant from the National Science Foundation to evaluate the ability of medical devices treated with Agile’s proprietary anti-biofilm compound, Agilyte™, to resist bacterial colonization.

According to Agile Sciences’ co-founder and Chief Scientific Officer John Cavanagh, “Bacteria on medical devices are particularly challenging to eradicate because they form a protective matrix called a biofilm on the surface of the device. Systemic use of antibiotics is generally ineffective against bacteria in biofilms, but Agile Sciences has developed the only compounds that are able to inhibit and disperse bacterial biofilms and also be covalently attached to polymer materials.”

Agile Sciences’ Chief Executive Officer, Keith Stoneback commented, “We expect that our compounds will effectively prevent the formation of bacterial biofilms on the surface of indwelling medical devices, which should lead to a clinically significant reduction in infection rates.”

Indwelling medical devices are associated with approximately 1 million infections and 50,000 deaths in the US each year, and hundreds of millions of dollars are spent annually treating these infections.

About Agile Sciences:
Agile Sciences is headquartered on North Carolina State University's Centennial Campus. The company was founded in 2007 by Professors Christian Melander and John Cavanagh of North Carolina State University (NCSU) to provide commercial solutions to those industries plagued by the effects of biofilms. The company's proprietary compounds are derived from the Agelas conifera sea sponge and have been shown to be effective in dispersing biofilms. For additional information, please visit:


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Keith Stoneback
Visit website